Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) have both demonstrated
impressive clinical activity in relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). …

Hepatitis E virus (HEV) is a small nonenveloped RNA virus usually transmitted by the
enteric route, although transmission by blood transfusion has also been reported. 1-3 HEV …

Prolonged Covid‐19 is an emerging issue for patients with lymphoma or immune deficiency.
We aimed to examine prolonged length of in‐hospital stay (LOS) due to Covid‐19 among …

Background Patients with lymphoma are immunocompromised because of the disease per
se and its treatments. We aimed to describe the characteristics of patients with lymphoma …

Background: Patients with hematological malignancies are at greater risk of severe COVID-19
and have been prioritized for COVID-19 vaccination. A significant proportion of them have …

Historically, double or triple hit lymphoma (DHL and THL) have poor outcomes with conventional
chemotherapy, but there is currently no guideline. We report the French experience in …

We assessed the long-term results of autologous stem-cell transplantation for patients with
first-relapsed or refractory Hodgkin lymphoma included in the prospective Lymphoma Study …

Although most classical Hodgkin lymphoma patients are cured, a significant minority fail after
primary therapy and may die as result of their disease. To date, there is no consensus on …

… Benedicte Deau-Fischer, Benedicte Deau-Fischer … Soledad Henriquez, Jérémie Zerbit,
Timothée Bruel, Amani Ouedrani, Delphine Planas, Paul Deschamps, Isabelle Staropoli …

Monoclonal antibodies (mAbs) against programmed cell death 1 (PD-1), such as nivolumab
and pembrolizumab, are associated with high response rates in patients with relapsed or …